Remicade (infliximab) reduces signs and symptoms of ulcerative colitis, inducing and maintaining clinical remission in these patients.
Remicade belongs to a class of drugs called tumor necrosis factor blockers, which suppress the immune system by blocking the activity of TNF, a substance that can cause inflammation and lead to autoimmune diseases.
Related Articles on Ulcerative Colitis:
Study: New Cytokine Provides Protection From Colitis
Study: P53, PUMA Independently Regulate IEC Apoptosis in Colitis
FDA Approves Wider Use of Lialda for Patients With Ulcerative Colitis
